Today's Pollen Forecast for 07981 :

Pollen Forecast 07981 :

LOW

Claritin-D® Efficacy

ADDRESS THE UNMET NEED OF NASAL CONGESTION

Nasal congestion has been reported by both patients and HCPs as one of the more bothersome symptoms for sufferers.

  • 4 out of 10 patients with allergic rhinitis rate nasal congestion as the most severe symptom1
  • 9 out of 10 HCPs rate nasal congestion as the most troublesome symptom to their patients with allergic rhinitis2

 

PATIENT DISSATISFACTION

Despite available treatments, many patients experience dissatisfaction with nasal congestion relief3,4

Reasons for potential dissatisfaction with nasal congestion relief

  • Incomplete symptom relief5
  • Patient perception of treatment ineffectiveness5
  • Slow speed of onset4
  • Short duration of relief5
  • Treatment side effects5
  • Patient misconception of perceived benefit of immediate or fast relief after first dose of INS spray6

INS=intranasal steroid

Claritin-D 24 hour and 12 hour day 4 improvements compared with placebo chart

Claritin-D® provides significant relief for patients with allergic rhinitis with nasal symptoms7

Claritin-D® starts to work in as little as 30 minutes8

  • Onset of action for allergies with nasal congestion in as little as 30 minutes8
  • Relief starts in 30 minutes, while an INS can take up to 12 hours for relief and can take between 3 to 14 days to reach maximum efficacy levels8-14,§
  • In a clinical study, Claritin-D® provided significantly greater relief of nasal congestion and runny nose vs placebo7

*Physician-evaluated scores.

P≤0.02.

P ≤0.05 vs placebo.

§INS onset based on various dosing instructions; time to maximum efficacy depends on the INS brand.

Adapted from Kaiser et al, 1998.

A double-blind, placebo-controlled, multicenter study involving 469 patients with mild-to-moderate SAR symptoms.

INS=intranasal steroid; SAR=seasonal allergic rhinitis.

Average Percent Change in PNIF - Claritin-D compared with placebo in nasal airflow improvement chart

In a clinical trial, Claritin-D® 12-hour provided 30% more nasal airflow at hour 115,*

*Based on max air intake through the nose after the first dose.

P<0.05 vs corresponding placebo.

Treatment phase baseline PNIF is from the highest of 3 measured values prior to study treatment. P values and estimates at each timepoint are from a mixed effects model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.

Note: The maximum PNIF value from each timepoint is summarized.

PNIF=peak nasal inspiratory flow.

Claritin-D 24 hour and 12 hour day 4 improvements compared with placebo chart

Claritin-D® 12-hour provided an improvement of nasal airflow at least 2 times more than Flonase at hour 115,*

*Based on max air intake through the nose after the first dose.

P<0.05 vs fluticasone nasal spray.

Treatment phase baseline PNIF is from the highest of 3 measured values prior to study treatment. P values and estimates at each timepoint are from a mixed effects model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.

Note: The maximum PNIF value from each timepoint is summarized.

Average Percent Change in PNIF - Claritin-D compared with placebo tablet, fluticasone nasal spray, and placebo nasal spray in nasal airflow improvement chart

Claritin-D® 12-hour:
Better outcomes at 240 minutes vs Flonase or placebo for entire study duration15

  • Average percent change in PNIF was significantly greater with Claritin-D® vs Flonase nasal spray or placebo throughout the study period

*P<0.05 vs fluticasone nasal spray.

P<0.05 vs corresponding placebo.

Treatment phase baseline PNIF is from the highest of 3 measured values prior to study treatment. P values and estimates at each timepoint are from a mixed effects model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.

Note: The maximum PNIF value from each timepoint is summarized.

PNIF=peak nasal inspiratory flow.
 

Claritin-D relief of 8 symptoms compared with Flonase relief of 6 symptoms comparison graphic

CLARITIN-D® IS INDICATED TO RELIEVE MORE TYPES OF ALLERGY SYMPTOMS THAN FLONASE BASED ON APPROVED LABEL INDICATIONS

Woman blowing nose into a tissue with Claritin-D package in foreground

CLARITIN-D® PATIENT TYPES

  • Patients with allergic rhinitis with nasal congestion
  • Patients concerned about drowsiness
  • Patients seeking once-daily treatment
  • Patients who want nasal congestion relief
  • Patients already on Claritin® who want to add a decongestant
  • Patients who appreciate an oral tablet vs a spray
Samples and coupons - Collection of Claritin packages

CLARITIN® SAMPLES & COUPONS

Claritin® offers allergy relief for kids and adults in a variety of forms and flavors.

Help your patients tackle their tough allergy symptoms with samples and coupons for Claritin® products.

References: 1. Meltzer EO, Farrar JR, Sennett C. Findings from an online survey assessing the burden and management of seasonal allergic rhinoconjunctivitis in US patients. J Allergy Clin Immunol Pract. 2017;5(3):77-789. doi:10.1016/j.jaip.2016.10.010 2. Blaiss MS, Meltzer EO, Derebery MJ, Boyle JM. Patient and healthcare-provider perspectives on the burden of allergic rhinitis. Allergy Asthma Proc. 2007;28(Suppl 1):S4-S10. doi:10.2500/aap.2007.28.2991 3. Meltzer EO, Blaiss MS, Naclerio RM, et al. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc. 2012;33(Suppl 1):S113-S141. doi:10.2500/aap.2012.33.3603 4. Keith PK, Desrosiers M, Laister T, Schellenberg RR, Waserman S. The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. Allergy Asthma Clin Immunol. 2012;8(1):1-11. doi:10.1186/1710-1492-87 5. Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin lmmunol. 2009;124(3 Suppl):S43-S70. doi:10.1016/j.jaci.2009.05.013 6. Allergy & Asthma Network. Understanding allergies. 2020. 7. Kaiser HB, Banov CH, Berkowitz RR, et al. Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis. Am J Ther. 1998;5(4):245-251. 8. Georgitis JW, Meltzer EO, Kaliner M, Weiler J, Berkowitz R. Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge. Ann Allergy Asthma lmmunol. 2000;84(4):451-459. 9. Flonase® website. Accessed December 8, 2021. https://www.flonase.com/faqs/ 10. Flonase®. Prescribing Information. GlaxoSmithKline; 2019. 11. Flonase® website. Accessed December 8, 2021. https://www.gskhealthpartner.com/en-us/respiratory-health/brands/flonase-products/flonase/dosing-administration-flonase-allergy-relief/ 12. Nasacort® website. Accessed December 8, 2021. https://www.nasacort.com/hcp/faqs.html 13. Nasacort®. Prescribing Information. Sanofi-Aventis; 2008. 14. Rhinocort® website. Accessed December 8, 2021. https://www.rhinocortprofessional.com/clinical-data/onset 15. Ng CC, Romaikin D, Steacy LM, et al. Comparative nasal airflow with loratadine-pseudoephedrine and fluticasone nasal spray for allergic rhinitis. Ann Allergy Asthma Immunol. 2021;S1081-1206(21)00348-3. doi:10.1016/j.anai.2021.05.001 16. Claritin-D® 12 Hour Drug Facts. NDA019670. 17. Flonase® Drug Facts. NDA205434.